-
1
المؤلفون: Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators
المساهمون: UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Hematology, CCA - Cancer Treatment and quality of life, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9)
المصدر: Leukemia, Vol. 35, no.1, p. 143-155 (2021)
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Leukemia, 35(1), 143-155. Nature Publishing Group
Leukemia
Leukemia, Springer Nature, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, 143-155. Nature Publishing Group
ISSUE=1;STARTPAGE=143;ENDPAGE=155;ISSN=0887-6924;TITLE=Leukemia
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & for the ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5مصطلحات موضوعية: 0301 basic medicine, Male, cd52 expression, Cancer Research, epstein-barr-virus, medicine.medical_treatment, CHOP, Gastroenterology, PROPHYLAXIS, 0302 clinical medicine, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, Medicine, Significant risk, Alemtuzumab, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, Hematology, lymphoproliferative disorders, Hazard ratio, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, 3. Good health, Treatment Outcome, Oncology, Vincristine, 030220 oncology & carcinogenesis, Toxicity, PHASE-II, Female, medicine.drug, medicine.medical_specialty, prognostic-factors, Medication Adherence, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Humans, non-hodgkin-lymphoma, Cyclophosphamide, Aged, Chemotherapy, therapy, business.industry, Lymphoma, T-Cell, Peripheral, DETUDE-DES-LYMPHOMES, medicine.disease, Survival Analysis, Peripheral T-cell lymphoma, 030104 developmental biology, Doxorubicin, Prednisone, business
وصف الملف: application/pdf
-
2دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
3دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
4
المؤلفون: Hanneke C. Kluin-Nelemans, Joost J. Oudejans, W. L. J. Van Putten, Marleen Luten, G. W. van Imhoff, P. J. Lugtenburg, M. van Marwijk Kooy
المساهمون: Hematology, Erasmus MC other, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL)
المصدر: Annals of Oncology, 22(7), 1595-1600. Elsevier Ltd.
Annals of Oncology, 22(7), 1595-1600. Oxford University Pressمصطلحات موضوعية: Male, Antibodies, Neoplasm, LYMPHOPROLIFERATIVE DISORDERS, CHOP, T-cell non-Hodgkin's lymphoma, Gastroenterology, Prednisone, Antineoplastic Combined Chemotherapy Protocols, alemtuzumab, T-cell lymphoma, NON-HODGKINS-LYMPHOMAS, Antibodies, Monoclonal, Hematology, Middle Aged, CHEMOTHERAPY, PROLYMPHOCYTIC LEUKEMIA, Survival Rate, Treatment Outcome, Oncology, Tolerability, Vincristine, PHASE-II, Alemtuzumab, Female, TRIAL, medicine.drug, Adult, medicine.medical_specialty, Adolescent, CD52 EXPRESSION, ANTI-CD52 MONOCLONAL-ANTIBODY, Antibodies, Monoclonal, Humanized, AGGRESSIVE LYMPHOMAS, Young Adult, EBV, Internal medicine, medicine, Humans, Cyclophosphamide, Survival rate, Aged, business.industry, Lymphoma, T-Cell, Peripheral, medicine.disease, Peripheral T-cell lymphoma, immunochemotherapy, Doxorubicin, CAMPATH-1H, Immunology, business, Follow-Up Studies
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6796645af7a587d9d3c754c65e8d92b5
https://pure.eur.nl/en/publications/60d3a921-8e93-46bb-a44f-d9d8d3d0da86 -
5دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
6دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
7دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
8دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
9دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
10دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.